Comparison of the cytotoxicity of the nitroaromatic drug flutamide to its cyano analogue in the hepatocyte cell line TAMH: evidence for complex I inhibition and mitochondrial dysfunction using toxicogenomic screening.
Flutamide (FLU) is an antiandrogen primarily used in the treatment of metastatic prostate cancer. It is an idiosyncratic hepatotoxicant that sometimes results in severe liver toxicity. FLU possesses a nitroaromatic group, which may be a contributor to its mechanism of toxicity. A nitro to cyano analogue of FLU (CYA) was synthesized and used to test this hypothesis in the TGFalpha-transfected mouse hepatocyte cell line (TAMH). MTT cell viability assays and confocal microscopy showed that hepatocytes are more sensitive to cytotoxicity caused by FLU than CYA (LD 50 75 vs 150 microM, respectively). Despite the structural modification, the antiandrogen activity of CYA is comparable to that of FLU. Comparisons of transcriptomic changes caused by FLU with those caused by a panel of known cytotoxicants [acetaminophen, tetrafluoroethylcysteine, diquat, and rotenone (ROT)] indicated that FLU results in a temporal gene expression pattern similar to ROT, a known inhibitor of complex I of the electron transport chain. A subsequent microarray analysis comparing FLU to CYA and ROT revealed many similarities among these three compounds; however, FLU and ROT result in more substantial changes than CYA in the expression of genes associated with oxidative phosphorylation, fatty acid beta-oxidation, antioxidant defense, and cell death pathways. Electron microscopy confirmed that FLU leads to mitochondrial toxicity that has some similarities to the mitochondrial effects of ROT, but the morphologic changes caused by FLU were greater in scope with both intra- and intercellular manifestations. Biochemical studies confirmed that both ROT and FLU deplete cellular ATP levels and inhibit complex I of the electron transport chain to a greater extent than CYA. Thus, as compared to CYA, the nitroaromatic group of FLU enhances cytotoxicity to hepatocytes, likely through mechanisms involving mitochondrial dysfunction and ATP depletion that include complex I inhibition.
Coe
Kevin J
KJ
Department of Medicinal Chemistry, University of Washington, Seattle, WA 98195, USA.
Jia
Yankai
Y
Ho
Han Kiat
HK
Rademacher
Peter
P
Bammler
Theo K
TK
Beyer
Richard P
RP
Farin
Frederico M
FM
Woodke
Libby
L
Plymate
Stephen R
SR
Fausto
Nelson
N
Nelson
Sidney D
SD
D000255:Adenosine Triphosphate / Q000032:analysis / Q000378:metabolism; D000726:Androgen Antagonists / Q000494:pharmacology; D000818:Animals; D045744:Cell Line, Tumor; D002470:Cell Survival; D004305:Dose-Response Relationship, Drug; D004354:Drug Screening Assays, Antitumor; D042967:Electron Transport Complex I / Q000037:antagonists & inhibitors* / Q000187:drug effects / Q000235:genetics; D005485:Flutamide / Q000737:chemistry* / Q000494:pharmacology*; D005786:Gene Expression Regulation; D022781:Hepatocytes / Q000187:drug effects* / Q000648:ultrastructure; D006801:Humans; D007928:Lethal Dose 50; D008297:Male; D051379:Mice; D046228:Microarray Analysis; D008928:Mitochondria / Q000187:drug effects*; D015394:Molecular Structure; D009570:Nitriles / Q000737:chemistry* / Q000494:pharmacology; D009574:Nitro Compounds / Q000737:chemistry* / Q000494:pharmacology; D011471:Prostatic Neoplasms / Q000188:drug therapy*
D000726:Androgen Antagonists; D009570:Nitriles; D009574:Nitro Compounds; D005485:Flutamide; D000255:Adenosine Triphosphate; D042967:Electron Transport Complex I
Life Sci. 2001 Dec 14;70(4):471-82
11798015
Toxicol Appl Pharmacol. 2007 Apr 1;220(1):92-107
17275868
Drug Metab Dispos. 2006 May;34(5):828-35
16507648
Genome Biol. 2003;4(10):R70
14519205
Expert Opin Drug Metab Toxicol. 2005 Jun;1(1):75-90
16922654
J Biol Chem. 2003 Nov 28;278(48):48292-9
14500711
J Pharmacol Exp Ther. 2003 Oct;307(1):1-8
12954806
J Urol. 1996 Jan;155(1):209-12
7490837
Rev Esp Enferm Dig. 2001 Jul;93(7):423-32
11685939
Res Commun Chem Pathol Pharmacol. 1980 Jun;28(3):447-56
7403659
Mol Carcinog. 2005 Dec;44(4):242-51
16240454
Biochem Pharmacol. 1995 Sep 28;50(7):1113-9
7575670
Cancer Res. 1994 Nov 15;54(22):5964-73
7525051
Drug Saf. 2002;25(9):633-48
12137558
Proc Natl Acad Sci U S A. 2007 Mar 20;104(12):5205-10
17360324
Cancer Res. 1989 Aug 15;49(16):4435-40
2743332
Prostate. 2006 Aug 1;66(11):1177-93
16652386
Life Sci. 2006 May 15;78(25):2889-97
16378625
Genome Biol. 2001;2(11):SOFTWARE0002
16173164
Curr Opin Drug Discov Devel. 2003 Jan;6(1):81-91
12613279
Biochem Pharmacol. 1996 Oct 25;52(8):1147-54
8937421
Hepatology. 2003 Jan;37(1):136-47
12500198
Bioinformatics. 2003 Jan 22;19(2):185-93
12538238
Hepatology. 2003 Oct;38(4):1053-5
14567386
Drug Metab Dispos. 2007 Jul;35(7):1081-8
17403914
J Pharmacol Exp Ther. 1994 Jun;269(3):954-62
8014883
Curr Opin Allergy Clin Immunol. 2003 Aug;3(4):235-42
12865765
Biochem Pharmacol. 2002 Aug 1;64(3):413-24
12147292
J Pharmacol Exp Ther. 1991 May;257(2):714-9
1851835
Genome Biol. 2004;5(10):R80
15461798
Curr Drug Metab. 2003 Aug;4(4):292-312
12871046
Biochemistry. 1975 Apr 22;14(8):1626-32
164892
J Pharmacol Exp Ther. 1993 Apr;265(1):366-72
8386241
Drug Discov Today. 2003 Sep 15;8(18):832-7
12963319
Biochim Biophys Acta. 1969 Feb 25;172(2):331-3
4304726
Arch Biochem Biophys. 2006 Oct 1;454(1):7-15
16962985
J Biol Chem. 1989 Jun 15;264(17):9814-9
2524496
Stat Appl Genet Mol Biol. 2004;3:Article3
16646809
Toxicol Lett. 2003 Mar 20;139(1):67-75
12595159
Toxicol Lett. 1992 Jul;61(2-3):275-81
1641873
J Pharmacol Exp Ther. 1994 Jul;270(1):167-76
8035313
Am J Med. 1992 May;92(5):465-70
1349790
Genome Biol. 2003;4(5):P3
12734009
Prostate. 2004 Nov 1;61(3):276-90
15368471
Curr Drug Metab. 2006 Oct;7(7):715-27
17073576
Drug Metab Rev. 2004 Oct;36(3-4):805-22
15554248
Drug Metab Dispos. 2006 Jun;34(6):984-92
16540588
Biochemistry. 2002 May 28;41(21):6789-97
12022883
Drug Metab Dispos. 2001 Feb;29(2):141-4
11159803
Toxicol Lett. 2001 Mar 31;120(1-3):359-68
11323195
Arch Toxicol. 2001 Sep;75(7):425-38
11693184
Drug Metab Rev. 2006;38(4):769-89
17145701
Nat Methods. 2005 May;2(5):351-6
15846362
Toxicol Sci. 2000 Feb;53(2):340-51
10696782
Pharmacol Toxicol. 2003 Sep;93(3):105-15
12969434
Chem Biol Interact. 2002 Nov 10;142(1-2):7-23
12399152
Biochim Biophys Acta. 2006 Sep-Oct;1757(9-10):1301-11
16836974
Chem Res Toxicol. 2006 Mar;19(3):480-90
16544956
Drug Metab Dispos. 2006 Jul;34(7):1266-75
16611858
Pharmacoepidemiol Drug Saf. 2006 Apr;15(4):253-9
16294367
J Biol Chem. 2004 Sep 17;279(38):39846-55
15247300